A Phase 2 study of HCW9218 in combination with chemotherapy and/or immune checkpoint inhibitors against solid tumors in patients with ovarian cancer
Latest Information Update: 21 May 2024
At a glance
- Drugs Antineoplastics (Primary) ; HCW 9218 (Primary) ; Immune checkpoint protein inhibitors (Primary)
- Indications Ovarian cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors HCW Biologics
Most Recent Events
- 15 May 2024 According to a HCW Biologics media release, the company announced that patient enrollment is expected to begin in the second half of 2024.
- 01 Apr 2024 According to a HCW Biologics media release, the company announced that this study will be sponsored by the University of Pittsburgh Medical Center.
- 20 Nov 2023 New trial record